The GLOW stack is a three-component research blend that pairs GHK-Cu, BPC-157, and TB-500 in a single vial. The name is an acronym drawn from the components rather than a description of any result, and the three peptides are chemically unrelated to one another — a copper-binding tripeptide, a gastric-derived pentadecapeptide, and an actin-binding peptide fragment. This explainer covers what each molecule actually is at the structural level, and what published research has measured for each in laboratory models. You can see the combined GLOW blend on its product page; this article is about the chemistry behind it.
What the GLOW stack is
“GLOW” is a label applied to a fixed combination of three distinct research peptides supplied together. A blend is simply three separate molecules co-located in one container, each with its own structure, class, and body of literature. The three are:
- GHK-Cu — the copper(II) complex of a naturally occurring tripeptide.
- BPC-157 — a synthetic pentadecapeptide (15 amino acids) whose sequence corresponds to a fragment of a protein identified in gastric juice.
- TB-500 — a synthetic peptide corresponding to the actin-binding region of the protein thymosin β-4.
Because the components are chemically independent, the most accurate way to understand the blend is to understand each molecule on its own terms. The sections below do exactly that, and in each case the physiological language is confined to what cited studies measured in research models rather than any outcome attributed to a person.
GHK-Cu: a copper-binding tripeptide
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine — three amino acids in sequence: glycine, histidine, and lysine (Gly-His-Lys, abbreviated GHK). The histidine residue gives the peptide a strong affinity for copper ions, so in the presence of copper(II) it forms a stable complex; that complexed form is what is written as GHK-Cu. The underlying GHK tripeptide was originally isolated from human plasma, which makes it a naturally occurring sequence rather than a purely designed one.
In the published literature, GHK and its copper complex have been studied as modulators of gene expression and extracellular-matrix turnover. A review of the molecule’s biochemistry catalogued research in cell and tissue models reporting effects on the expression of genes involved in collagen and glycosaminoglycan synthesis and in tissue remodeling (Pickart et al., BioMed Research International, 2015). Those are descriptions of what investigators measured in their experimental systems — the citation is the claim.
BPC-157: a gastric-derived pentadecapeptide
BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids. The abbreviation BPC stands for “Body Protection Compound,” and the sequence corresponds to a partial fragment of a larger protein that was identified in human gastric juice. In other words, BPC-157 did not originate as a de novo designed drug; it was derived from a naturally observed protective protein, and the 15-residue fragment that retained activity in early experiments became the compound studied under the BPC-157 name. It is manufactured synthetically and is reported to be stable in gastric juice, a property that distinguishes it from many small peptides that degrade rapidly.
BPC-157 has been characterized almost entirely in animal and cell models. A wide-ranging review by the group that first described the peptide summarized decades of preclinical work positioning it within the framework of gastric cytoprotection (Sikiric et al., Gut and Liver, 2019). A separate study examined the peptide in a rat model of injured myotendinous junctions, reporting measurements relevant to connective-tissue repair in that model (Japjec et al., Biomedicines, 2021). Both citations describe findings in research subjects, not effects in people.
TB-500: an actin-binding peptide fragment
TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin β-4, a small, naturally abundant protein found in many tissues. Thymosin β-4 itself is a 43-amino-acid polypeptide and is regarded as the principal G-actin–sequestering peptide in cells, meaning it binds monomeric actin and influences the assembly of the actin cytoskeleton. TB-500 reproduces the short, central actin-binding motif of that parent protein rather than the full-length molecule, which is the structural reason it is described as a fragment or analog rather than as thymosin β-4 itself.
Research on thymosin β-4 and its actin-binding motif has been conducted in cell and animal models. One study localized the angiogenic activity of thymosin β-4 to its actin-binding site, reporting that the isolated motif drove endothelial cell migration in assays comparably to the full protein (Philp et al., FASEB Journal, 2003). A broader review described the protein’s role as an actin-sequestering molecule and surveyed tissue-repair–related findings across experimental systems (Goldstein et al., Trends in Molecular Medicine, 2005). Again, these are measurements made in laboratory models.
How GLOW relates to KLOW
GLOW is frequently discussed alongside a closely related four-component blend called KLOW. The relationship is straightforward arithmetic at the level of ingredients: KLOW is GLOW plus one additional peptide, KPV. KPV is a synthetic tripeptide (lysine-proline-valine) corresponding to the C-terminal fragment of the larger α-melanocyte–stimulating hormone (α-MSH) sequence. So the two blends share the same GHK-Cu / BPC-157 / TB-500 base, and the only structural difference is the presence or absence of that fourth tripeptide.
Put simply:
- GLOW = GHK-Cu + BPC-157 + TB-500 (three components).
- KLOW = GHK-Cu + BPC-157 + TB-500 + KPV (four components).
If you want the version that adds the KPV tripeptide, the KLOW blend is the corresponding four-component product. Choosing between them is a question of which set of research molecules a given study design calls for.
Frequently asked questions
What is the GLOW stack made of?
The GLOW stack is a research blend of three distinct peptides: GHK-Cu (a copper-binding tripeptide), BPC-157 (a 15-amino-acid pentadecapeptide), and TB-500 (a fragment corresponding to the actin-binding region of thymosin β-4). They are chemically unrelated molecules supplied together in one vial.
What does GHK-Cu stand for?
GHK-Cu denotes the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. “GHK” is the single-letter shorthand for that glycine–histidine–lysine sequence, and “Cu” is the chemical symbol for copper, which the peptide binds.
What does BPC-157 stand for?
BPC stands for “Body Protection Compound.” BPC-157 is a synthetic pentadecapeptide whose sequence corresponds to a fragment of a protein originally identified in gastric juice.
Is TB-500 the same as thymosin beta-4?
No. Thymosin β-4 is the full 43-amino-acid protein. TB-500 is a synthetic peptide corresponding to its shorter actin-binding motif, so it is a fragment or analog of the parent protein rather than the complete molecule.
What is the difference between GLOW and KLOW?
KLOW is GLOW with one additional peptide. Both contain GHK-Cu, BPC-157, and TB-500; KLOW also includes KPV, a lysine-proline-valine tripeptide derived from the α-MSH sequence.
Are these peptides approved for human use?
No. GHK-Cu, BPC-157, and TB-500 are research compounds studied in laboratory and animal models, and the products discussed here are intended for laboratory research only, not for human or veterinary use.
References
- Pickart L, et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015. PMID: 26236730.
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020. PMID: 31158953.
- Japjec M, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines. 2021. PMID: 34829776.
- Philp D, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. 2003. PMID: 14500546.
- Goldstein AL, et al. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005. PMID: 16099219.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
